行情

OCX

OCX

ONCOCYTE
NASDAQ
0.4752
+0.0051
+1.08%
已收盘, 18:46 12/01 EST
开盘
0.4700
昨收
0.4701
最高
0.4877
最低
0.4512
成交量
55.22万
成交额
--
52周最高
2.680
52周最低
0.3545
市值
5,637.95万
市盈率(TTM)
-0.7253
分时
5日
1月
3月
1年
5年
OncoCyte 首席执行官 Ronnie Andrews 辞职
OncoCyte 首席执行官 Ronnie Andrews 辞职
MT Newswires · 1天前
OncoCyte 从美国退伍军人事务部获得合同;股票跳跃
OncoCyte 从美国退伍军人事务部获得合同;股票跳跃
MT Newswires · 08/30 16:36
OCX 简况
OncoCyte Corporation is a molecular diagnostics company. The Company is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

微牛提供OncoCyte Corp(NASDAQ-OCX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的OCX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易OCX股票基本功能。